Get the Stockscreener App
0.86
0.46%
-0.000050
Profusa Inc stock is traded at $0.86, with a volume of 30,201.
It is down -0.46% in the last 24 hours and down -70.89% over the past month.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.
See More
Previous Close:
$0.8599
Open:
$0.86
24h Volume:
30,201
Relative Volume:
0.05
Market Cap:
$1.17M
Revenue:
$75,000
Net Income/Loss:
$-39.09M
P/E Ratio:
-0.00303
EPS:
-283.719
Net Cash Flow:
$-11.45M
1W Performance:
-14.33%
1M Performance:
-70.89%
6M Performance:
-97.53%
1Y Performance:
+0.00%
1-Day Range:
$0.85
$0.875
1-Week Range:
$0.82
$1.03
52-Week Range:
$0.82
$166.50
Profusa Inc Stock (PFSA) Company Profile
Name
Profusa Inc
Sector
Industry
Phone
212-494-9022
Address
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Compare PFSA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.86 | 1.17M | 75,000 | -39.09M | -11.45M | -283.72 |
|
ABT
Abbott Laboratories
|
109.81 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
345.58 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.64 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
68.57 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.60 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Profusa Inc Stock (PFSA) Latest News
Profusa (PFSA) & Its Peers Financial Contrast - Defense World
PFSA Earnings History & Surprises | EPS & Revenue Results | PROFUSA INC (NASDAQ:PFSA) - ChartMill
PFSA SEC FilingsProfusa Inc 10-K, 10-Q, 8-K Forms - Stock Titan
PFSA Financials: Income Statement, Balance Sheet & Cash Flow | Profusa Inc - Stock Titan
Profusa, Mayo Clinic to Advance Clinical Applications of Oxygen Monitoring Technologies - Medical Product Outsourcing
Head-To-Head Comparison: Profusa (PFSA) versus Its Competitors - Defense World
PFSA Technical Analysis & Stock Price Forecast - Intellectia AI
Profusa cancels $15M public offering, plans smaller fundraise By Investing.com - Investing.com Canada
Profusa cancels $15M public offering, plans smaller fundraise - Investing.com South Africa
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering - GlobeNewswire
Biotech Profusa scraps $15M stock sale after revenue outlook shifts - Stock Titan
Biosensor technology company Profusa Inc announced that revenue from its Lumee oxygen monitoring product in the European market is expected to receive substantial support starting from the second quarter of 2026. - Bitget
Profusa’s Market Moves as Revenue Reports Spark Uncertainty - StocksToTrade
Profusa Inc. Stock Declines Amid Financial Struggles and Market Uncertainty - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Profusa (PFSA) vs. Its Competitors Head-To-Head Review - Defense World
Analyzing Profusa (PFSA) and The Competition - Defense World
CapsoVision (NASDAQ:CV) and Profusa (NASDAQ:PFSA) Head-To-Head Review - Defense World
Contrasting Profusa (PFSA) & Its Rivals - Defense World
Contrasting Profusa (PFSA) & Its Peers - Defense World
Profusa raises 2026 revenue forecast on European purchase orders By Investing.com - Investing.com South Africa
Profusa raises 2026 revenue forecast on European purchase orders - Investing.com Nigeria
Profusa Raises 2026 Revenue Guidance to $3 Million Amid Strong Demand - Intellectia AI
Profusa Receives Purchase Orders for Lumee™ Tissue Oxygen Monitoring and Raises 2026 Revenue Guidance - The Manila Times
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Profusa (PFSA) and Its Rivals Head to Head Analysis - Defense World
Contrasting Profusa (PFSA) & Its Competitors - Defense World
PFSA Should I Buy - Intellectia AI
Profusa (PFSA) & Its Peers Head-To-Head Review - Defense World
Head to Head Contrast: Profusa (NASDAQ:PFSA) versus Biosig Technologies (NASDAQ:STEX) - Defense World
Profusa announces initial $1 million bitcoin investment to initiate its digital asset treasury strategy - MSN
Profusa, Mayo Clinic Partner on Oxygen Monitoring License - TipRanks
Profusa and Mayo Clinic collaborate to advance high-impact clinical applications of oxygen monitoring technologies - marketscreener.com
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies - The Manila Times
Profusa Lags Rivals in Key Business Metrics - National Today
Mayo Clinic, Profusa explore continuous oxygen monitor for surgery - Stock Titan
Profusa Shares Fall 27% Following 1-for-75 Reverse Stock Split Becoming Effective - Nasdaq
Profusa Executes Significant 1-for-75 Reverse Stock Split - TipRanks
Profusa to shrink share count from 92.4M to 1.2M in reverse split - Stock Titan
Profusa Announces 1-for-75 Reverse Stock Split - The Manila Times
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Profusa (PFSA) wins approval for reverse stock split range up to 1-for-200 - Stock Titan
Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Contrasting Profusa (NASDAQ:PFSA) & Longevity Health (NASDAQ:XAGE) - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
PFSA Forecast — Price Prediction for 2026. Should I Buy PFSA? - Intellectia AI
Profusa restructures senior secured convertible notes - MSN
Profusa launches tissue oxygen monitoring system for research market By Investing.com - Investing.com Nigeria
Profusa Stock Spikes As Lumee System Targets Research Market - Benzinga
Profusa Launches Lumee, Paving Way For First Commercial Revenue; Stock Jumps - Nasdaq
Profusa launches tissue oxygen monitoring system for research market - Investing.com
Profusa Inc Stock (PFSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):